Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

EVO-PDAC

Financiado

Evolutionary dynamics of pancreatic cancer at single-cell and spatial levels

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, a disease with a dismal prognosis. PDAC has an especially high tendency of quickly metastasizing and becoming resistant to therapy, and the mech... ver más

31/08/2026

EMBL

174K€

Presupuesto del proyecto: 174K€

Líder del proyecto

EUROPEAN MOLECULAR BIOLOGY LABORATORY No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-05-14

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

EMBL

173.85K€ | Lider

Proyectos interesantes

PID2021-124106OB-I00 TERAPIAS PERSONALIZADAS EN CANCER DE PANCREAS 508K€ Cerrado

PID2021-128125OB-I00 UNA APROXIMACION INTEGRATIVA HACIA LA PREVENCION DEL CANCER... 496K€ Cerrado

SAF2014-59864-R UN ABORDAJE MULTIDISPLINAR PARA DESARROLLAR NUEVAS VIAS TERA... 702K€ Cerrado

RTI2018-094507-B-I00 MECANISMOS DE METASTASIS EN EL CANCER DE PULMON 182K€ Cerrado

PANCAID PANcreatic CAncer Initial Detection via liquid biopsy 10M€ Cerrado

RTI2018-101071-B-I00 FACTORES DE TRANSCRIPCION EN CANCER DE PANCREAS: DE LA BIOLO... 399K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 27 meses Fecha Inicio: 2024-05-14
Fecha Fin: 2026-08-31

Presupuesto del proyecto 174K€

Descripción del proyecto Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, a disease with a dismal prognosis. PDAC has an especially high tendency of quickly metastasizing and becoming resistant to therapy, and the mechanisms by which this occurs are largely unknown. Recent evidence suggests that saltatory or burst-like evolution mediated by complex genomic rearrangements (CGRs) may be especially relevant in PDAC, altering multiple cancer genes in a single event. However, quantifying CGRs requires specialized techniques (such as Strand-Seq), and therefore the relative importance of CGRs, simple structural variants, and point mutations in PDAC evolution remains unclear. In this project, we will use a genetically engineered mouse model (GEMM) that develops de novo PDAC to longitudinally track PDAC evolution by single-cell and spatial multi-omic methods, using Strand-Seq to accurately detect CGRs. Thus, we aim to create longitudinal single-cell and spatial multi-omic atlases of PDAC at three key evolutionary steps: pre-cancer, therapy-naive PDAC, and post-therapy PDAC. In addition, we will compare our atlases to human PDAC data from the Spatial And Temporal Resolution of Intratumoral Heterogeneity in 3 hard-to-treat Cancers (SATURN3) Consortium. In this way, we will model PDAC evolution at various time points, quantifying the relative importance of gradual vs saltatory evolution and determining how evolvability changes over time. Moreover, we will infer the role of selective pressures from the tumor microenvironment (e.g., immune cells and cancer-associated fibroblasts) in shaping PDAC evolution. Finally, we will explore how all these factors interact with the high intratumoral heterogeneity observed in PDAC. Overall, this project will answer long-standing questions about the evolutionary dynamics of PDAC.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores